APA (7th ed.) Citation

Zhu, C., BinJadeed, H., Gabrielli, S., Prosty, C., Rahme, E., Shand, G., . . . Netchiporouk, E. (2024). Prevalence of omalizumab-resistant chronic urticaria and real-world effectiveness of dupilumab in patients with omalizumab-refractory chronic urticaria: A single-centre experience. Clinical & Experimental Dermatology, 49(10), 1227. https://doi.org/10.1093/ced/llae145

Chicago Style (17th ed.) Citation

Zhu, Catherine, Hessah BinJadeed, Sofianne Gabrielli, Connor Prosty, Elham Rahme, Greg Shand, Michael Fein, Moshe Ben-Shoshan, and Elena Netchiporouk. "Prevalence of Omalizumab-resistant Chronic Urticaria and Real-world Effectiveness of Dupilumab in Patients with Omalizumab-refractory Chronic Urticaria: A Single-centre Experience." Clinical & Experimental Dermatology 49, no. 10 (2024): 1227. https://doi.org/10.1093/ced/llae145.

MLA (9th ed.) Citation

Zhu, Catherine, et al. "Prevalence of Omalizumab-resistant Chronic Urticaria and Real-world Effectiveness of Dupilumab in Patients with Omalizumab-refractory Chronic Urticaria: A Single-centre Experience." Clinical & Experimental Dermatology, vol. 49, no. 10, 2024, p. 1227, https://doi.org/10.1093/ced/llae145.